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Abstract:
Objective: To assess the efficacy of plasma rich proteins (PRP) compared to placebo in the treatment of
androgenetic alopecia (AGA).
Design: Systematic literature review
Methods: Searches were done in PubMed utilizing the terms PRP, plasma rich protein, autologous
activated PRP, autologous activated plasma rich protein, androgenetic alopecia, placebo, hair count, hair
density, hair follicles, hair loss, therapeutic effect, growth factors, dermatology, and regenerative
medicine. Articles were excluded if they were published before 2013, involved animal studies,
compared minoxidil only in their research, included only female participants, non-English articles,
studies with no quantifiable data, review research articles, and injections besides the scalp
Results: A meta-analysis yielded five adequate articles meeting both the inclusion and exclusion criteria
including 143 patients. All five studies resulted in beneficial outcomes and statistically significant
results in patients treated with PRP.
Conclusion: PRP injections revealed clinically significant improvement in hair growth and density
along with overall patient satisfaction. PRP injections were shown to be well tolerated with mild pain
and without any major adverse effects.
Keywords: platelet-rich plasma; androgenetic alopecia; growth factors; hair growth; restoration; hair
loss; injection therapy
Abbreviations: AGA: androgenetic alopecia; PRP: platelet-rich plasma; PDGF: platelet-derived growth
factor; VEGF: vascular endothelial growth factor; PDAF: platelet derived angiogenic factor; TGF-b:
transforming growth factor beta; MPHL: male pattern hair loss; FGF-7: fibroblast growth factor-7; PPP:
platelet poor plasma

Introduction:
Platelet-rich plasma (PRP) is an autologous preparation of platelets in concentrated
plasma that contains a platelet concentration above basal concentration1. When the platelet-a
granules become activated, numerous growth factors are released. Growth factors such as
platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal
growth factor, and platelet derived angiogenic factor (PDAF), transforming growth factor beta
(TGF-b), and insulin-like growth factor are hypothesized to stimulate cell proliferation and
differentiation as well as vascularization and angiogenesis.
When injected, the patient’s own platelets accelerate the healing of injured ligaments,
tendons, joints, and muscles.2 Aside from musculoskeletal benefits, PRP has also been identified
as having beneficial effects on bone grafting in oral and maxillofacial surgery, orthopedic and
cardiac surgery, and more recently, dermatology3. The use of PRP in dermatology has shown to
aid in tissue regeneration, fat grafting, skin rejuvenation, wound healing, and alopecia.
Androgenetic alopecia is commonly known as male pattern baldness4. It is most
commonly observed in Caucasian men over the age of 50, affecting up to 80% of this population.
Although named male pattern baldness, women are not excluded, affecting predominantly
Caucasian women after menopause. Androgenic alopecia is considered to be a mild, non-life
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threatening dermatologic condition, but psychological consequences such as depression are
commonly associated.
The specific etiology of AGA is largely unknown with several genetic and environmental
factors thought to contribute. Androgens, a predominantly male hormone, has been associated
with this type of hair loss due to its role in regulating hair growth. The normal cycle of hair is
disrupted when there are increased androgens in the hair follicle, resulting in both shorter and
thinner hair strands as well as delayed regrowth of hair follicles5. The hair loss is primarily
observed bilaterally in the temporal area as well as the vertex in men, while it can also affect the
anterior and mid-scalp.4 In women, the hair loss tends to be diffuse thinning without a receding
hairline.
When treating androgenic alopecia, growth factors released from platelets may have an
effect on stem cells in the bulge area of hair follicles by stimulating the development of new
follicles and promoting neovascularization6. Primitive stem cells, originating from the
ectodermal origin, are found in the bulge area, thus giving rise to sebaceous glands and
epidermal cells. Similarly, mesenchymal stem cells in the matrix are found at the dermal papilla7.
When the ectodermal stem cells, mesenchymal stem cells, and growth factors converge, the
proliferative phase of hair growth is activated and prolonged, giving rise to a follicular unit8.
Individually, each growth factor has a role in the development and maintenance of new
hair follicles. Platelet derived growth factor (PDGF) stimulates stem cell mitosis while
transforming growth factor-b (TGF-b) activates the dermal papilla and inhibits apoptosis during
the cell cycle9. Vascular endothelial growth factor (VEGF) helps by promoting microcirculation
during the follicular growth process10.
This paper will complete a comprehensive analysis of research, investigating if PRP does
in fact improve AGA outcomes.

Methods:
An initial search of PubMed was performed in September 2020 using the terms: PRP,
plasma rich protein, autologous activated PRP, autologous activated plasma rich protein,
androgenetic alopecia, placebo, hair count, hair density, hair follicles, hair loss, therapeutic
effect, growth factors, dermatology, and regenerative medicine. See Figure 1. The preliminary
search resulted in 42 articles. Investigators excluded articles that were published before 2013,
involved animal studies, compared minoxidil only in their research, included only female
participants, non-English articles, studies with no quantifiable data, review research articles, and
injections besides the scalp. After excluding 35 articles based on exclusion criteria, 7 articles
were left. Furthermore, the researchers excluded articles that did not use autologous activated
PRP or studies that did not measure androgenetic alopecia exclusively, thus yielding 5 articles to
be used in the meta-analysis.
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Results:
The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized PlaceboControlled Trial11
Study Objective: To assess the effectiveness of plasma rich protein versus placebo on hair
regrowth through a randomized, evaluator-blinded, placebo-controlled, half-head group study.
The safety and clinical efficacy of autologous PRP injections for pattern hair loss were also
investigated.
Study Design:
Participant Selection: The diagnosis of male pattern hair loss (MPHL) was established based on
a detailed medical history (excluding those taking any medications causing hair loss),clinical
examination, trichoscopic features, and laboratory tests. Laboratory tests were used to exclude
other hair loss causes such as poor nutrition, thyroid dysfunction, anemia, and syphilis and
included: complete blood count, serum iron, serum ferritin, total iron-binding capacity, folic
acid, T3, T4, thyroid stimulating hormone, fT3, fT4, antithyroid peroxidase, testosterone, and a
Venereal Disease Research Laboratory blood test for syphilis. The stage of alopecia was
evaluated using the Hamilton-Norwood scale. Inclusion criteria were age 19-63 years old, male
pattern hair loss from stage IIa to stage IV according to the Hamilton-Norwood classification,
and the patient was considered suitable for PRP injections from a surgical standpoint. There were
two types of exclusion criteria: local and systemic. The systemic criteria included platelet
disorders, thrombocytopenia, antiaggregating therapy, systemic treatments for MPHL
(finasteride, dutasteride, antiandrogens) in the past 12 months, bone marrow aplasia,
uncompensated diabetes, sepsis, and cancer. Local criteria included MPHL stages V-VII and
topical treatments for MHPL (minoxidil, prostaglandin, analogs, retinoids, and corticosteroids) in
the past 12 months. 23 male participants were selected and were all assessed by two experts in
plastic surgery.
Protocol:
PRP Preparation: PRP was prepared from a small volume of blood (18 mL) according to
the method of the Cascade-Selphyl-Esforax system with modifications and from 60 mL
of blood according to the Platelet Rich Lipotransfert system with modifications. Blood
was taken peripherally, used sodium citrate as an anticoagulant, and then was centrifuged
depending on the system. The final aim was to create a platelet pellet. Growth factors
were secreted once platelet activation began, which was stimulated by calcium. About 9
mL of PRP was harvested for each patient.
Injection: For each participant, the scalp was divided into four areas: frontal, parietal,
vertex, and occipital. The area was cleaned with 70% alcohol and local anesthesia was
not administered. PRP was injected into select areas of the scalp and were performed
with a 30-gauge, 1 mL syringe. Interfollicular injections of PRP were performed 3 times
in each patient at intervals of 30 days. See in Figure 2. Patients with hair loss localized to
the frontal and parietal areas were injected with the PRP only in the frontal areas while
the parietal area was treated with placebo. Those with hair loss in the parietal and vertex
parts of the scalp were injected with PRP only on the parietal section while the vertex
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area was treated with placebo. The same number of injections were repeated in the scalp,
half treated with PRP and the other half treated with placebo.
Measurements: All patients were evaluated in 6 stages: T0, the beginning of the study;
T1, 2 months after last injection; T2, 6 months; T3, 12 months; T4, 16 months; and T5,
24 months. The effects of the treatment on hair growth were assess in all patients with the
help of global photography, physician and patient’s goal assessment scale, and
standardized phototrichograms. Phototrichograms were taken of all scalps by a trained
evaluator using the Fotofinder video-epiluminescence microscopy in combination with
the Trichoscan digital image analysis, which measures hair count, hair density, hair
diameter, anagen-to-telogen ratio, and vellus hair-to-terminal hair ratio. Incisional punch
biopsies (diameter of 3 mm) were also taken of the hair skin at baseline and after 2
months from the last PRP injection. Morphometric analysis was performed on
hematoxylin-and-eosin stained paraffin serial sections by evaluating the thickness of
epidermis and the number of follicles per mm . All samples were cut perpendicularly at
the skin surface and embedded. Finally, immunohistochemistry was performed using
mouse monoclonal anti-Ki67. The percentage of Ki67 cells in the basal layer of the
epidermis and in the outer root sheath of hair follicles, and the number of vessels per mm
were calculated according to morphometric criteria.
2

2

Figure 2: Injections of PRP into the scalp

Study Results:
At baseline, there were no statistical differences in hair count, hair density, and terminal and
anagen hair densities between the PRP treatment and control area of the scalp. The results of the
study showed a significant increase in the mean hair count for the treatment area after 3 months
compared to baseline, with a mean increase of 33.6 hairs in the target area for PRP while the
control area showed a mean decrease of 3.2 hairs (P<0.0001). For hair density, there was a mean
increase in total hair density of 45.9 hairs per cm compared with baseline after 3 months in the
treatment group while there was a mean decrease of 3.8 hairs per cm in the control group
(P<0.0001). Terminal hair density improved significantly by 40.1 hairs per cm in the treatment
area compared with the baseline, while it decreased by 5.6 hairs per cm in the control area (P=
0.0003). There were no statistically significant differences in vellus hair density between the
study and the control area after 3 months.
2

2

2

2
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Microscopic evaluation showed an increase in epidermis thickness in the PRP treated scalp after
2 weeks form the last injection compared to the baseline value (P<0.05). There was also an
increase in the number of follicles compared to the baseline value in the treatment area (P<0.05).
The researchers also investigated the proliferation of epidermal and hair follicular bulge cells.
After 2 weeks from the last injection, they observed an increase of Ki67 basal keratinocytes of
epidermis and of hair follicular bulge cells compared to baseline (P<0.05). PRP treatment was
also associated with increased angiogenesis around hair follicles in the treated skin compared
with the baseline measurements. (P<0.05)
+

Relapse of androgenic alopecia was not evaluated until 12 months after the last injection. Out of
the 23 participants, 4 reported progressive hair loss that was evident 16 months after their last
PRP injection. These patients were treated again with 3 PRP injections.
Study Critique: A limitation to this study included a small sample size and then need for a more
controlled, complex, and large study to further investigate. Also, the study mentioned that they
checked for evidence of relapse of androgenic alopecia 12 months after the last injection. They
reported that 4 patients had relapsed and were re-treated. However, a follow up should have been
done to see if other patients relapsed past the 12-month mark or if those patients that had been retreated, had relapsed again.

Treatment of male pattern alopecia with platelet-rich plasma: A double-blind
controlled study with analysis of platelet number and growth factor levels12
Study Objective: Analyze the platelet count and growth factor levels in PRP and their
correlation with hair growth parameters evaluated by using the TrichoScan compared to placebo.
Study Design:
Participant Selection: The diagnosis of androgenetic alopecia was based on personal history of
progressive hair loss for more than 2 years as well as inversion of percentages of anagen and
telogen hairs and a decrease in hair density on the TrichoScan. Inclusion criteria included
diagnosis of androgenetic alopecia, age between 18-50 years old, and AGA-III-vertex profile
according to the Hamilton-Norwood scale. Exclusion criteria comprised of female sex, previous
hair transplantations, history of any disease related to hair loss, use of anti-platelet or antiinflammatory drugs, and present or history of past neoplasia, kidney, liver, infectious,
hematologic, or rheumatoid disease. 26 patients were selected and were randomized into 2
groups. One group received PRP injections while the other acted as the control group, receiving
saline.
Protocol:
Obtaining PRP: For each patient, peripheral blood was collected in six 8.5 mL acid
citrate dextrose tubes, one 4 mL ethylenediaminetetraacetic acid tube, and 1 tube without
anticoagulant. A preparation of PRP with leukocytes was prepared and the platelets were
counted in the baseline and in the PRP samples using Siemens Advia2120i hematology
analyzers. Autologous serum was prepared from the tube without anticoagulant: after
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centrifugation at 1258 g for 15 minutes, 1 mL was separated and then added to the PRP
syringe right before the application. The entire procedure was carried out in a laminar
flow cabinet, and all materials were sterile. PRP samples were normalized to a
concentration of 1200 3 106 platelets/"L and activated with autologous serum.
Injection: In this double-blinded study, 26 patients were randomized to receive 4
subcutaneous injections of either PRP or saline to the scalp. A 32-gauge needle with a 1
mL syringe was used to perform the injections. In total, 4 applications were carried out
every 15 days and the treated area was anesthetized with 10% lidocaine ointment 15
minutes before each injection.
Measurements: Baseline measurements of hair growth, hair density, percentage of
anagen and telogen hairs, and percentage of vellus and terminal hairs were taken before
the injection using the TrichoScan. Measurements were taken 15 days after last injection
and again 3 months after last injection.
Study Results: The parameters of hair growth were evaluated using the TrichoScan in both
groups. Prior to treatment, the control group patients presented with more hair and higher hair
density than those in the PRP group (P=0.041).
Clinical Evaluation: Compared to the placebo group, the PRP group showed a more significant
increase in hair count, hair density, and percentage of anagen hairs. See Figure 3.
For hair count, the PRP group showed a significant increase in counts before application
and 3 months after the last application (P=0.016). The control group also showed a slight,
but not significant, increase in hair count as well (P=0.320).
Regarding hair density, the PRP group displayed a significant increase between the
baseline and follow up values (P=0.012) compared to the control group was no difference
was observed (P=0.206).
Anagen percentages were significantly increased in the PRP group when comparing the
baseline measurements to after 15 days post injection (P=0.007). However, between the
15 days post injection measurement and 3 months post injection measurement, the
increase was not maintained (P=0.703). With the control group, there was no significant
increase during any of the evaluations. Telogen percentages are proportionally inverse to
the anagen percentages, thus, there was a significant decrease in the PRP group between
the first two evaluations, but it was not maintained during the final measurement.
The terminal to vellus ratio showed no significant different in the PRP group or in the
control group when comparing the ratios before and after treatment (P= 0.955 PRP, P=
0.206 control)
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Figure 3: Clinical measurements comparing PRP to control groups at baseline, 15 days after last
injection, and 3 months post injection.

PRP Characterization and Growth Factors: The median number of platelets was increased 5
fold in each of the 4 PRP preparations, with a minimum of 728.9 and a maximum of 1901.90.
However, despite the increase in platelet count in PRP, there was no correlation between the
platelet counts and any of the growth parameters evaluated in the study (P=0.123 for hair count,
P=0.086 for hair density, P= 0.171 for percentage of anagen and telogen hairs, and P=0.174 for
percentage of vellus and terminal hairs).
Study Critique: A limitation of the study was that they did not measure all growth factors or
signaling pathways that could contribute to hair growth.
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A Spilt Head Study of Efficacy of Placebo versus Platelet-rich Plasma
Injections in the Treatment of Androgenic Alopecia13
Study Objective:
This study's objective was to compare the efficacy of placebo versus PRP injections in male
androgenic alopecia.
Study Design:
Participant Selection: These men had to have a diagnosis of androgenic alopecia with HamiltonNorwood Grade III to VI, and must not have used minoxidil or oral finasteride in the past 6
months. Patients were excluded if they had a hematological clotting disorder, were on
anticoagulant therapy, thyroid dysfunction, malnutrition or other dermatological disorders that
may be contributing to the hair loss. They were also excluded if they had unrealistic expectations
or any inter-current infections. The men ranged from 18 to 55 years old with the mean age being
34 years old.
Protocol:
Obtaining PRP: A total of 16ml of blood was drawn utilizing an 18-gauge needle and
divided into containers of 8ml each. A double spin method was performed. They were
placed in the centrifuge for 8 minutes at 1200rpm. Once completed, the platelet poor
plasma (PPP) was transferred into another tube via a pipette. This tube was spun faster at
2400rpm for 4 minutes. The top layer of PPP was removed, leaving the PRP that was
then drawn into an insulin syringe.
Injections; In order to evaluate the efficacy of each, the autologous PRP was injected by
intradermal technique via insulin syringes into the left side of the scalp where androgenic
hair loss was present and normal saline was injected into the right side of the scalp. A
1cm x 1 cm square area was marked in the parietal area in the mid-pupillary line
bilaterally. A total of 1-2cc was injected. A total of six treatments were performed every
21 days in a total of 44 men.
Measurements: TrichoScan, a tool that follicular units are able to be counted and track
hair thickness and hair density was completed at baseline and each subsequent visit.
Along with this, a hair pull test was performed twice at each follow up along with photos
of the frontal, vertex, lateral back view of the scalp. The pull test was done by grasping
approximately fifty pieces of hair and firmly tugged. The patient's subjective results were
also completed.
Study Results:
Results show that at the baseline the average number of hairs pulled on the hair pull test was
eights and was reduced to three hairs by the third and fourth visit which is considered normal.
The photos taken at each visit showed subjective improvement in hair growth as seen in Figure
4.
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Figure 4: Before and after treatment of a 28 year-old male

The null hypothesis that there will be no difference of the mean hair density in the right side
versus the left side of the scalp was ultimately rejected. A paired t-test comparing the hair
density between the left and right side of the scalp after the first treatment and after the sixth
treatment significantly improved as shown in Figure 5.
Figure 5: Mean hair density at T1 and T6
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Once all six treatments were completed, patients were asked to complete a satisfaction
questionnaire. Based on a 1-10 scale, with 1 being no result and 10 being the best result, the
average result was a 7.0. Of the 44 patients involved in the study, 70% reported improvement in
hair quality and thickness and 55% perceived an increase in hair density.
Study Critique:
The downfall of this study was the subjective evaluation of the hair pull test. Unfortunately, an
objective measurement utilizing a trichogram was not available. However, the methods used in
this study are reproducible. Another downfall includes the small sample of patients which did not
allow the study to validate the results.

Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess
the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic
Alopecia14
Study Objective:
To assess the efficacy of PRP in the treatment of androgenetic alopecia.
Study Design:
Participant selection: This study was a randomized, double-blind, placebo-controlled study. 25
individuals including 12 men and 13 women selected to participate were 18-65 years old
(average of 39 years old) with a diagnosis of androgenic alopecia. A total of 22 patients
completed the study in its entirety while 3 individuals were lost to follow up. Therefore, there
were 11 men and 11 women evaluated. Men included must have had Hamilton-Norwood patterns
II-V while women selected were Ludwig Stage I-III. The exclusion criteria consisted of any
topical or oral medication use indicated for hair growth, laser therapy or chemotherapy with the
previous 12 months. Those with bleeding disorders, platelet dysfunction syndrome, platelet
counts less than 150,000 uL; those who had taken anticoagulants or NSAIDS in the past 2 weeks,
smokers, women that were pregnant or lactating. If the individual had an additional chronic scalp
condition or had previous hair transplants, they were also excluded.
Protocol:
Obtaining PRP: A total of 18 mL of each patient's blood was placed into a tube with 2mL
of 3.8% sodium citrate. This tube was centrifuged for 8 minutes at 460g. The upper layer
of PPP was removed leaving PRP. Calcium chloride was added to the PRP portion
immediately before injection.
Injections: A total of four areas of the scalp were marked in circular areas measuring 1cm
x 1cm and injected with 0.15mL/cm2.
Local anesthesia was not used. Half of the scalp was treated with PRP while the other
half was treated with saline, the placebo. Participants were randomly divided into two
groups, and placed in either group A or group B. Group A’s right half of the scalp was
treated with PRP while the left was treated with placebo. Group B was the opposite; the
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left side treated with PRP while placebo was used on the right side of the scalp. This is
displayed in Figure 6. The physician injecting was not blinded to the solution being
injected due to the difference in color and consistency.
Measurements: Results were documented via global photography and phototrichogram.
The evaluator was blinded to which side of the scalp was placebo and not involved in the
treatment portion of the study. The vertex, frontal, and occipital portions of the scalp
were photographed utilizing a standardized medical photography system and software.
TrichoScan was utilized to analyze microscopic images of the 4 treated areas. The hair
count and density along with terminal hair density, anagen and telogen percentage and
anagen to telogen ratio were analyzed.
Each participant was evaluated a total of 4 visits, while receiving treatment the first 3
visits spaced a month apart. The final visit was 6 months from the baseline visit.
Evaluative measurements were documented at 3 months and 6 months. The participants
were also treated with 3 treatments of PRP on the placebo area of the scalp once the study
was completed.
Figure 6: 1 frontal and 1 occipital area on each half of the scalp. For group A, the right half of
the scalp was treated with PRP and left half treated with placebo.

Study Results:
Results were analyzed using a mixed procedure SAS 9.2. The study was statistically significant
with p < 0.5.
The mean anagen hairs, telogen hairs, hair density and terminal hair density significantly
improved from baseline to after 3 months and 6 months. After 3 and 6 months, the total hair
density increased on the PRP treated area compared to baseline. The mean total hair density after
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3 months on the PRP treated areas resulted in a mean increase of 14.8 + 32.1 hairs/cm2 when
compared to baseline. The placebo side in fact results in a decreased total hair density of 0.7 +
32.7 hairs/cm2. At the final follow up, of 6 months, the PRP treated area had a mean increase in
total hair density of 12.8 + 32.6 hairs/cm2 with a decrease of 2.1 + 31.3 hairs/cm2 on the control
side. Therefore, the results were statistically significantly comparing the control with the treated
with p <0.05 after both 3 and 6 months.
Unfortunately, there was no statistically significant increase in the total hair count between the
PRP and placebo treated area, but a minimal increase of hair count was observed on the PRP
treated side. Between the PRP and placebo treated areas, there was no statistical difference in the
vellus hair density.
Statistically significant data was correlated with mean total hair density in men, but not women.
Those that had hair loss begin >25 years, had a family history of androgenetic hair loss and a
greeted than 10 years of evolution of androgenetic alopecia were found to have statistically
significant improvement with PRP treatment compared to placebo.
An increase in anagen hair percentage correlated with participants older than 40 and an onset of
androgenetic alopecia at 25 or more years old at the conclusion of the study.
Study Critique: The patients were evaluated at a short time frame of only 6 months. Therefore,
the long-term benefits of PRP cannot be concluded. Benefits of this study included having the
patient treated with both placebo and PRP to avoid any bias of gender or amount of hair loss.
This study also had a small sample size which makes it difficult to interpret on a larger
population.

The Clinical Efficacy and Safety of Autologous Activated Platelet-Rich
Plasma Injection in Androgenetic Alopecia15
Study Objective:
To assess the efficacy of autologous PRP in androgenetic alopecia patients.
Study Design:
Participant selection: This study included 28 total patients with 27 of them being male and 1
female with a diagnosis of androgenetic alopecia. They ranged from 20-50 years old and must
not have used any topical or systemic medications in the past 6 months for treatment of hair loss.
Patients were excluded if they have other dermatologic conditions of the scalp, history of
immunosuppression, history of keloids, autoimmune diseases, platelet dysfunction or other
hematologic disorders or were currently on anticoagulants. Before being the trial, other causes of
the hair loss was excluded by receiving a complete blood count, thyroid function tests. Women
also received follicle stimulating hormone, luteinizing hormone and testosterone levels. The hair
loss was classified using the Hamilton-Norwood scale in men and Ludwig classification for
females. Men ranged from type II-VII while the female was classified by the Ludwig scale as III.
Protocol:
Obtaining PRP: Dr. PRP kit was used to prepare the PRP. First. 18mL of blood was
combined with 2mL sodium citrate and placed into the PRP kit. The solution was
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centrifuged at 3000rpm (3 minutes for women and 4 minutes for men). A second
centrifugation was completed for six minutes at 3,200 rpm. The PPP was removed and
the remaining 4mLor PRP was transferred to a syringe. Prior to injection, calcium
gluconate was added to activate the platelets.
Injections: Topical anesthetic cream was applied 1 hour prior to injection and the PRP
was injected using the Nappage technique. This technique is linear injections spaced 1cm
between at depth of 1.5-2.5mm. Patients were treated for a total of three sessions spaced
three weeks apart and a fourth session 14 weeks from the first treatment.
Measurements: The patient’s progress was measured at six points including baseline,
three weeks, six weeks, nine weeks, 14 weeks and again post treatment at six and seven
months. Evaluation was completed utilizing macrophotography and dermoscopic
photography. The same area of the scalp was evaluated on the dermoscopic images
assessing the hair count manually and hair density calculated based on hairs per cm2. The
test utilized were two-tiled and were considered statistically significant if <0.05. All
patients were given a satisfaction questionnaire at their final visit (T6).
Study Results:
A total of 28 patients completed the study including 23 males and 1 female. The average age was
31. Compared to baseline the total hair density statistically increased each treatment with a p
value of <0.001. Hair density measured at T6, which was 7 months post baseline, was 161.83 +
20.687 while baseline was 102.25 + 18.463. Figure 7
Macroscopic photographs subjectively showed an improvement in appearance of hair density
and quality. Based on the satisfaction questionnaire, of 0 being not satisfied and 100 being
satisfied, the mean score from patients was 72.92. All the patients reported mild pain, but
adverse side effects were noted.
Figure 7: Mean standard deviation of hair density at timed intervals

Study Critique: This study compared the final results to baseline rather than a placebo.

RUNNING HEAD: THE EFFECT OF PLATELET RICH PLASMA ON ANDROGENETIC 16
ALOPECIA

Discussion:
Androgenetic Alopecia remains the most common hair disorder without satisfactory treatment
with only hair transplants and drug therapies such as minoxidil and finasteride as solutions.
Characterized by a shortened anagen phase and smaller terminal-to-vellus hair ratio, AGA
therapies target cellular proliferation and differentiation during the hair cycle.
Evidence suggests the antipoptotic effect of PRP has a major role in stimulating hair growth by
prolonging the survival of the dermal papilla cells during the hair cycle. Furthermore, the
upregulation of FGF-7/-catenin signaling pathways with PRP is proposed to stimulate hair
growth by inducing follicular stem cell differentiation in addition to prolonging the anagen phase
of the hair growth cycle. Additionally, PRP increases the perifollicular vascular plexus with the
increase of VEGF and PDGF.
All 5 studies that were reviewed demonstrated that PRP had a significant improvement in hair
count, hair density, and overall hair growth in patients with androgenetic alopecia compared to
the placebo. An overview of the 5 articles assessed is provided in Table 1.
Of the 5 studies chosen, Kachhawa et al had the largest sample size of 44, with the other
articles having a smaller sample of about 25 participants. Also, the majority of the studies
chose to conduct research on males exclusively, with the exception of Paththinige et al
who had 3.5% female participation and Alves et al whose population was composed of
50% female. All studies focused on an age range of young adults to individuals in their
50s and 60s, all of whom suffered from androgenetic alopecia.
In terms of the type of study, all were blinded studies and compared PRP and a placebo,
with the exception of Paththinige et al who injected all of the participants with PRP and
compared the results to baseline measurements. Also, Gentile et al, Kacchawa et al, and
Alves et al investigated PRP’s effect versus placebo with a split head study, meaning that
the scalp was divided into sections and half of the scalp would receive the PRP injection
while the other remaining half would have saline injected. Due to the patient serving as
both the control as well as receiving the treatment, there is reduced variability in
outcomes. Rodrigues et al was the only study that had a separate PRP group of
participants and compared that to a control group.
The results from the selected studies reviewed suggest PRP to be a promising therapeutic
potential for the treatment of AGA. All 5 studies showed positive results and PRP
efficacy was assessed by multiple measurements and endpoints. Gentile et al and
Rodrigues et al relied on objective findings such as hair density, hair count, and vellousto-terminal hair ratios. Kacchawa et al and Paththinige et al included subjective findings
such as the pull test and overall patient satisfaction. Finally, Alves et al and Paththinige et
al utilized global photography to compare the effects of PRP before and after treatment.
The volume of blood drawn, the centrifuge settings, mean platelet enrichment, activator
used, treatment protocol and duration all varied between each of the studies. Treatment
protocols ranged from 3-6 visits with time intervals spaced 15 days to 30 days. Follow up
also ranged from 4.5 months after initial treatment to 2 years.
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Table 1: Overview of 5 Studies Reviewed
Overview of Studies Reviewed

Gentile
et al

Rodrigues
et al

Kachhawa
et al

Alves
et al

Paththinige
et al

Patient, N

23

26

44

22

28

Population

19-63 year old
males with
androgenetic
alopecia
(MPHL stages
IIa-IV)

18-50 year old
males with
presentation
of AGA III
vertex profile
according the
HamiltonNorwood
scale.

18-55 year
old males
with
diagnosis of
androgenic
alopecia
with
HamiltonNorwood
Grade III to
VI

18-65 year old
males and
females/ Men
selected had
HamiltonNorwood
patterns II-V
while women
selected were
Ludwig Stage IIII.

20-50 year old
males and
females with
androgenetic
alopecia

Gender

M: 100%

M: 100%

M: 100%

M: 50%
F: 50%

M: 96.5%
F: 3.5%

Duration of
Study

injections
every 30 days
x 3 visits

20 injections
(totaling 2
mL) every 15
days x 4 visits

A total of
six
treatments
were
performed
every 21
days

Injections once
a month x 3
visits

4 PRP
treatments at
baseline,3
weeks, 6
weeks, and at
14 weeks

Follow up

2 years

2 years

4.5 months

6 months

7 months
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PRP
Preparation

CasacadeSelphylEsforax system
(single spin;
1100g for 10
min); Platelet
Rich
Lipotransfert
system (single
spin; 1200 rpm
for 10 min);
sodium citrate
as anticoag

Amable et al
method:
autologous
serum was
prepared
without
anticoag,
single spin
(1258g for 15
min); 1 mL of
serum was
added to
blood sample
with citrate
acid.

Double spin
method of
1200 rpm
for 8
minutes and
again at
2400 rpm
for 4
minutes

Single spin with
addition of
sodium citrate
at 460g for 8
minutes

Double spin
method
Utilizing the
Dr. PRP Kit

Blinding Study

Evaluator
blinded

Double
blinded

Double
blinded

Double
blinded

Compares to
baseline with
no placebo

Groups

Half-head
group study
(PRP vs.
placebo)

PRP (n=15)
and control
(n=11)

Half-head
group study
(PRP vs
control)

Half-head group
study (PRP vs
control)

All patients
treated with
PRP

Endpoints
(Measurements)

Hair count,
hair density,
terminal vs.
vellus hair
density

Hair count,
hair density,
anagen
percentage,
terminal-tovellus ratio

Hair
thickness
and density
along with a
hair pull test
and patient
satisfaction
scores

Global
photography,
hair count and
density along
with terminal
hair density,
anagen and
telogen
percentage and
anagen to
telogen ratio
were analyzed.

Macroscopic
Photography,
hair count and
hair density.
Satisfaction
questionnaires.
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Among the 5 studies reviewed, one major limitation was the lack of standardized treatment
protocol application of PRP in addition to standardized evaluation methods. When describing the
PRP preparation for each study, there was a lack of consensus regarding the addition of
activators, the amount of time spent in the centrifuge and speed, platelet concentration, and the
volume of blood used. Treatment protocols varied between the number of sessions, the time
interval between treatments, duration of treatment, and the follow period. Without standardized
procedures, it is difficult to adequately assess the efficacy of PRP for its therapeutic potential on
androgenetic alopecia patients when comparing different studies. Another limitation was that the
sample sizes of each study were relatively small, making it difficult to assess for efficacy. With
Paththinige et al, the study did not have a control group and only compared PRP’s effectiveness
to baseline measurements taken. Many studies were short in terms of duration and there was not
adequate enough time for follow up after the treatment phase. Only Gentile et al reported relapse
in 4 of their patients 16 months after treatment who were then retreated so it is unclear if other
studies had relapses given the shorter follow up time frame. Finally, with the subjective
measurements like the hair pull test and patient satisfaction questionnaires, it is difficult to
compare the efficacy of PRP as the pull test could have been performed differently each time as
well as patients might have had unrealistic expectations prior to starting treatment.
With the majority of the studies exclusively testing males, there could be some possible selection
bias as androgenetic alopecia can also affect women as well. Also, with the subjective patient
satisfaction questionnaires, the questions were not published, thus, making it difficult to assess
for any bias. There was no evidence of publication bias or funding/sponsorship bias with any of
the 5 studies reviewed.
All studies statistically compared each group’s measurements with p-values, which emphasized
that all results were statistically significant and not due to random chance. Of all the objective
measurement findings, all measurements for the PRP groups were proven to be statistically
significant with p-values<0.05, demonstrating PRP’s effectiveness compared to placebo which
showed many p-values >0.05.

Conclusion:
In males and females, ages 18-65, with androgenetic alopecia, do platelet rich plasma injections
more effectively treat hair growth (subjective and quantitative measures) compared to placebo?

PRP effectively improves hair growth and density is those affected by AGA with limited adverse
effects. The studies included in this analysis all compared to either placebo or baseline
measurements. In future studies, it would be beneficial to expand the research to compare PRP to
the current standard treatments of AGA, including Minoxidil and Finasteride. Looking forward,
it would be advantageous to create a standardized and qualitative measurement of results to
allow for uniform comparisons across studies. Further exploration of PRP with the addition of
growth factors in correlation to improved hair growth may also be beneficial.
PRP injections have proven to be safe with minimal invasiveness and no major adverse effects
noted. Mild pain during injection was the most reported side effect. Of the five 5 studies, no
infection or ecchymosis was reported by patients, nor visualized during follow-up care. The
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downside of PRP injections at this point in time is cost. Minoxidil and finasteride continue to be
the only FDA approved treatments for AGA. With PRP injections considered as off-label
treatment for AGA, it's likely not to be covered by insurance. Overall, PRP is a minimally
invasive and effective alternative treatment for AGA.
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